Showing results (51-60 of 89) with videos related to
Sort By:
Pageof 9
Plos One|November 9, 2016
CMV+ Serostatus Associates Negatively with CD4:CD8 Ratio Normalization in Controlled HIV-Infected Patients on cARTIsabelle Poizot-Martin, Clotilde Allavena, Claudine Duvivier, et al.Plos One|June 6, 2020
The effects of chikungunya virus infection on people living with HIV during the 2014 Martinique outbreakMathilde Pircher, Edwin Pitono, Sandrine Pierre-François, et al.HIV Clinical Trials|October 9, 2004
An example of nonrandom missing data for hepatitis C virus status in a prognostic study among HIV-infected patientsCharlotte Lewden, Hélène Jacqmin-Gadda, Jean-Louis Vildé, et al.Therapie|August 5, 2006
[Analysis of antiretroviral drugs-induced adverse effects]Magalie Baudrant, Haleh Bagheri, Lise Cuzin, et al.HIV Clinical Trials|January 28, 2017
Quality of life improvement in HIV-1 patients treated with raltegravir in a real-life observational study: RACINGBruno Spire, Lella Nait-Ighil, Pascal Pugliese, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|September 19, 2012
Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 studyLise Cuzin, Selma Trabelsi, Pierre Delobel, et al.BMC Infectious Diseases|May 4, 2013
Missed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional studyKaren Champenois, Anthony Cousien, Lise Cuzin, et al.Plos One|November 1, 2016
Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical PracticePierre Gantner, Firouze Bani-Sadr, Rodolphe Garraffo, et al.Journal of Virology|September 29, 2006
Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapyPierre Delobel, Marie-Thérèse Nugeyre, Michelle Cazabat, et al.Pageof 9